THE HEMOSTATIC ACTIVITY OF BIS (2-AMINOETHAN-1-SULFONATE) CALCIUM
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i11.29049Keywords:
Taurate of calcium, Hemostasis system, Proaggregatory activity, Hemostatic activityAbstract
Objective: It is known that local or systemic injection of hemostatic drugs is used to reduce blood loss and number of blood transfusions in patients with hypocoagulation and hemorrhagic diathesis. However, the analysis of literature data shows that the drugs applied for the control of bleeding, traditionally used in medical practice, are not effective enough. This study deals with the systemic hemostatic activity of bis (2-aminoethan-1- sulfonate) calcium in the experiment.
Methods: Experimental work in vitro is performed on the blood of healthy male donors, under conditions in vivo it is done on intraperitoneal injection in male rats. Thromboelastography was carried out with apparatus Thromboelastography (TEG) 5000 (Haemoscope Corporation, United States). The influence of first synthesized derivative and ethamsylate on functional activity of platelets was studied using a platelet aggregation analyzer Biola 230LA†(Russia). Experimental evaluation of the system specific hemostatic activity in vivo was carried out using the model of parenchymatous bleeding in mature male rats. The interference came amid registration of bleeding stop time and extent of blood loss.
Results: Bis (2-aminoethan-1-sulfonate) calcium shows procoagulation and proaggregant activity both in vitro and in vivo. Proaggregatory effect of bis (2-aminoethan-1-sulfonate) calcium is successfully implemented in the systemic hemostatic activity in terms of parenchymal bleeding, surpassing the control group and the group of etamsylate.
Conclusion: The results of these studies reveal potentially high systemic hemostatic activity of bis (2-aminoethan-1-sulfonate) calcium, urging the need for further study on this compound and its analogs to create on their basis highly efficient, selective correctors of the hemostatic system.
Downloads
References
Minasov BS, Yakupov SF, Yakupov RR, Minasov TB, Valeev MM, Mavlyutov TR. Comparative analysis of surgical treatment of unstable fractures of the clavicle. Creat Surg Oncol 2017;7:11-5.
Gantsev SK, Arybzhanov DT, Saburov AR. Results of treatment sick of the stomach cancer of IV stage. Creat Surg Oncol 2017;7:34-7.
Francoeur CL, Roh D, Schmidt JM, Mayer SA, Falo MC, Agarwal S, et al. Desmopressin administration and rebleeding in subarachnoid hemorrhage: Analysis of an observational prospective database. J Neurosurg 2018;1:1-7.
Zolotukhin KN, Krüger Ph, Samorodov AV. Low level of antithrombin III as a warning sign for developing trombotic complications in surgical patients. Creat Surg Oncol 2018;1:52-6.
Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U, et al. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013;27:1201-7.
Elbourne DS. Randomised controlled trial of prophylactic etamsylate: Follow up at 2 years of age. N Y Acad Sci 1987;205:9-13.
Urakov AL, Samorodov AV, Kamilov FK, Khaliullin FA, Gubaeva RA. Hemostatical activity of new benzylammonium salt 2-[3-methyl-1- n-propyl-7-(1,1-dioxotiethanyl-3)xantinyl-8-thio]acetic acid. Natl J Physiol Pharm Pharmacol 2017;11:1213-8.
Purygin PP, Ermokhin VA, Samorodov AV, Kamilov FK. Means With Systemic Hemostatic Effect. Patent RUS No. 2640131, 10.05.2017.
Khanam N, Alam I, Ali Y, Siddiqui AR. A review on optimization of drug delivery system with experimental designs. Int J App Pharm 2018;10:7-12.
Gangaraju S, Manjappa B, Subbaiah G, Kempaiah K, Shinde M, Sannaningaiah D. Anticoagulant and antiplatelet activities of jackfruit (artocarpus heterophyllus) seed extract. Int J Pharm Pharm Sci 2015;7:187-91.
Grif and C. Manual for Preclinical Studies of Medicaments. Part I. Moscow: Grif and C; 2012.
Verstraete M. Report on Ethamsylate. In: Haemostatic Drugs. Dordrecht: Springer; 1977.
Sweetmann SC. Martindale-The Complete Drug Reference. London: Pharmaceutical Press; 2002.
Jyothi NV, Bharathi DR, Prakruthi GM. Evaluation of drug-drug interactions in patients of general medicine, ICU and emergency departments at a tertiary care hospital. Int J Curr Pharm Res 2018;10:68 71.
Sack ES, Dujovne I. Effects of cyclonamine on blood platelets. I. Turbidimetric and electronmicroscopic studies. Medicina (B Aires) 1973;33:525-35.
Okuma M, Takayama H, Sugiyama T, Sensaki S, Uchino H. Effects of etamsylate on platelet functions and arachidonic acid metabolism. Thromb Haemost 1982;48:330-3.
Keith I. Ethamsylate and blood loss in total hip replacement. Anaesthesia 1979;34:666-70.
Schulte J, Osborne J, Benson JW, Cooke R, Drayton M, Murphy J, et al. Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2005;90:F31-5.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.